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ABSTRACT
Background: Spinal muscular atrophy (SMA) is the most
common inherited lethal disease of children. Various
genetic deletions involving the bi-allelic loss of SMN1
exon 7 are reported to account for 94% of affected
individuals. Published literature places the carrier
frequency for SMN1 mutations between 1 in 25 and 1 in
50 in the general population. Although SMA is considered
to be a pan-ethnic disease, carrier frequencies for many
ethnicities, including most ethnic groups in North
America, are unknown.
Objectives and methods: To provide an accurate
assessment of SMN1 mutation carrier frequencies in
African American, Ashkenazi Jewish, Asian, Caucasian,
and Hispanic populations, more than 1000 specimens in
each ethnic group were tested using a clinically validated,
quantitative real-time polymerase chain reaction (PCR)
assay that measures exon 7 copy number.
Results: The observed one-copy genotype frequency was
1 in 37 (2.7%) in Caucasian, 1 in 46 (2.2%) in Ashkenazi
Jew, 1 in 56 (1.8%) in Asian, 1 in 91 (1.1%) in African
American, and 1 in 125 (0.8%) in Hispanic specimens.
Additionally, an unusually high frequency of alleles with
multiple copies of SMN1 was identified in the African
American group (27% compared to 3.3–8.1%). This latter
finding has clinical implications for providing accurate
adjusted genetic risk assessments to the African
American population.
Conclusions: Differences in the frequency of SMA
carriers were significant among several ethnic groups.
This study provides an accurate assessment of allele
frequencies and estimates of adjusted genetic risk that
were previously unavailable to clinicians and patients
considering testing.
With an incidence of 1 in 6000 to 1 in 10 000 live
births, spinal muscular atrophy (SMA) is the most
common lethal genetic disease of children.
1 SMA is
a neuromuscular disorder that leads to progressive,
proximal muscle weakness and atrophy. Sixty per
cent of individuals affected with SMA have the
most severe form, type I, also known as Werdnig–
Hoffman disease (Online Mendelian Inheritance in
Man (OMIM) 253300), with clinical onset usually
occurring before 6 months and death by respira-
tory failure before the age of 2 years. Clinical onset
of type II SMA (OMIM 253550) usually occurs by
the age of 15 months with most cases surviving
beyond 10 years of age. Type II patients may learn
to sit, but never gain the ability to walk. Type III
SMA (OMIM 253400) is a milder form with onset
typically occurring between 2 and 17 years of age.
An adult form of SMA (type IV, OMIM 271150)
has also been described.
SMA is caused by mutations in the Survival
Motor Neuron 1 (SMN1) gene.
2 The SMN1 gene
resides in a duplicated region of chromosome 5q13
telomeric to the near identical homologue SMN2.
More than 90% of the functional SMN protein is
contributed by SMN1. Comparably SMN2 pro-
duces only a small fraction of SMN due to a point
mutation in exon 7 that disrupts an exon splice
enhancer site, preventing normal post-transcrip-
tion processing.
34 In the general population the
copy number of SMN1 and SMN2 genes varies.
Published information suggests that 85–95% of the
population has one copy of the SMN1 gene per
allele; however, individuals with more than one
copy per allele have been identified.
5–10 Ninety-four
per cent of affected individuals possess bi-allelic
mutations involving various deletion mutations
that share the loss of SMN1 exon 7. Of the
remaining 6% of SMA cases, most are attributed to
a variety of rare molecular lesions distributed
throughout the gene, including point mutations,
small insertions, and deletions. A minority of cases
may involve genes other than SMN1.
11
Additionally, there is an inverse correlation
between SMN2 copy number and disease severity,
such that affected individuals with three or more
copies of SMN2 typically have milder forms of the
disease.
12 This mutation spectrum permits sensitive
detection of carriers through the analysis of SMN1
exon 7 copy number by quantitative polymerase
chain reaction (PCR).
51 31 4In calculating the mean
from the results of their own and other published
research, Ogino et al reported a frequency for one-
copy carriers at approximately 1 in 40 individuals
in the general population.
15 In addition to the low
prevalence mutations distributed across the gene,
another small subset of carriers cannot be identi-
fied by exon 7 copy measurement since they have
one allele with two SMN1 copies paired with a
zero-copy allele (hereafter referred to as ‘‘2+0’’
genotype). By exon 7 quantification these indivi-
duals are indistinguishable from wild-type (or
‘‘1+1’’ genotype). It has been estimated that
approximately 1 in 600 apparent two-copy speci-
mens may be ‘‘2+0’’ carriers.
16
Recently published guidelines from the
American College of Medical Genetics (ACMG)
recommend universal carrier screening for SMA.
17
Before this guidance, carrier screening in the USA
was offered primarily to family members of
individuals diagnosed with SMA. SMA is consid-
ered to be pan-ethnic; however, published studies
to date have involved small and heterogeneous
sample sets.
5–8 15 16 Even the few studies addressing
specific races provide insufficient information to
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ments with the precision warranted by widespread carrier
screening.
14 18–20
To address this need for accurate allele frequency data, more
than 1000 samples from five major ethnic groups, African
American, Ashkenazi Jewish, Asian, Caucasian and Hispanic,
were tested for SMN1 copy number. These ethnicities are
relevant since they comprise .95% of the North American
population at large and the North American patients electing to
participate in genetic testing (2006 US Census estimates).
METHODS
Samples were collected from residual material following routine
clinical testing of individuals presumed to have no family
history of SMA. All specimens were made completely anon-
ymous before testing in accordance with approved institutional
protocols. Ethnic assignment relied upon patient reported data
that were not collected as part of complete family histories.
However, these ethnic assignments, which reflect clinical
practice, are therefore highly representative of the anticipated
clinical experience for SMA carrier screening. The assessment of
SMN1 exon 7 copy number employed a clinically validated, real-
time, quantitative PCR assay specific for the single nucleotide
change in exon 7 (cd 840 c.t). All reported results could be
assigned to validated, non-overlapping genotype groups of 1, 2
or 3 SMN1 copies (the three copies group includes samples with
three or more SMN1 gene copies).
RESULTS
Significant differences in the frequencies of SMN1 genotypes
were observed among several ethnicities (table 1). The highest
one-copy carrier rate was identified in specimens from the
Caucasian group with a frequency of 1 in 37 samples (2.7%).
This result agrees closely with those previously reporting on
European populations.
67The 1.8% carrier frequency detected in
the Asian sample group is comparable to the 1.6% and 1.9% that
have been reported in Southern Chinese populations.
14 20 The
African American and Hispanic groups had statistically sig-
nificant lower one-copy carrier genotypes when compared to
Caucasians, at 1 in 90 (1.1%, p=0.0089) and 1 in 125 (0.8%,
p=0.0007), respectively. These are the lowest SMN1 carrier
frequencies reported for any population or ethnic group at this
time. For all but the African American group, the two-copy
genotype was more than five times more prevalent than the
three-copy genotype group. This result is consistent with all
previously published data showing the two-copy genotype to be
predominant. Surprisingly, the African American population
departed significantly from this genotype distribution, revealing
similar frequencies for the two- and three-copy genotypes
(52.1% and 46.8% respectively), suggesting a much higher
frequency of alleles with two or more SMN1 copies than the
other four ethnic groups. These unexpected results in this group
were confirmed by retesting 10% of the samples using multi-
plexed ligation dependant probe amplification (MLPA, MRC
Holland, The Netherlands) as an alternate technique. All MLPA
results were concordant with the original real-time PCR data.
Using the observed genotype data and assuming Hardy–
Weinberg equilibrium, maximum likelihood estimation was
employed to determine frequencies for alleles and allele pairings
within all sample groups (tables 2 and 3). These calculations
reveal that the expected frequency of alleles with two or more
copies of SMN1 in the African American group is 3.4 to 8.4
times more prevalent when compared to the other ethnic
groups. The preponderance of the two-copy allele in the African
American group also suggests a much higher frequency of
individuals with the SMA carrier ‘‘2+0’’ genotype compared to
other ancestries.
Adjusted carrier risk assessment estimates have been pre-
viously published based on aggregate results of several
studies.
15 16 These estimates calculate the probability of being
an SMA carrier when an individual without a family history of
Table 1 Frequency of SMN1 copy number across various ethnicities
Ethnicity
1 copy 2 copies 3 copies
Total
n n Frequency (95% CI) n Frequency (95% CI) n Frequency (95% CI)
Caucasian 28 0.027 (0.019 to 0.039) 935 0.910 (0.89 to 0.93) 65 0.063 (0.05 to 0.08) 1028
Ashkenazi Jewish 22 0.022 (0.015 to 0.033) 827 0.825 (0.80 to 0.85) 153 0.153 (0.13 to 0.18) 1002
Asian 18 0.018 (0.011 to 0.028) 897 0.873 (0.85 to 0.89) 112 0.109 (0.09 to 0.13) 1027
African American 11 0.011 (0.006 to 0.019) 529 0.521 (0.49 to 0.55) 475 0.468 (0.44 to 0.50) 1015
Hispanic 8 0.008 (0.004 to 0.015) 870 0.845 (0.82 to 0.87) 152 0.148 (0.13 to 0.17) 1030
Table 2 Frequencies of SMN1 copies per allele for each ethnic group
Ethnicity 0121
D*
Caucasian 0.0142 0.9532 0.0318 0.0003
Ashkenazi Jewish 0.0121 0.9072 0.0825 0.0002
Asian 0.0096 0.9338 0.0571 0.0002
African American 0.0077 0.7188 0.2691 0.0001
Hispanic 0.0044 0.9188 0.0804 0.0001
*1
D=disease allele (not caused by exon 7 deletions—for example, point mutations)
as described by and based on frequency in SMA patients by Wirth et al (1999).
11 De-
novo mutations have also been described in spinal muscular atrophy (SMA) patients;
however, their frequency is sufficiently low (,2%) such that their inclusion in the
calculations causes no change to these results at the level of precision used here.
21
Table 3 Frequency of SMN1 allele pairings
Allele pairings Caucasian
Ashkenazi
Jewish Asian
African
American Hispanic
Non-carrier
2+2 0.0011 0.0065 0.0032 0.0748 0.0059
2+1 0.0621 0.1462 0.1058 0.3931 0.1416
1+1 0.9081 0.8230 0.8720 0.5169 0.8439
Total 0.9713 0.9756 0.9810 0.9848 0.9914
Carrier
2+1
D* 1.7E–05 3.6E–05 2.0E–05 7.7E–05 1.2E–05
2+0 0.0009 0.0019 0.0011 0.0041 0.0007
1+1
D 0.0005 0.0004 0.0003 0.0002 0.0001
1+0 0.0272 0.0220 0.0175 0.0108 0.0078
Total 0.0286 0.0243 0.0189 0.0152 0.0086
Affected
1
D+1
D* 7.1E–08 5.1E–08 2.0E–08 3.1E–08 6.2E–09
1
D+0* 7.6E–06 5.5E–06 2.1E–06 3.3E–06 6.7E–07
0+0 2.0E–04 1.5E–04 5.7E–05 8.8E–05 1.8E–05
Total 2.1E–04 1.5E–04 5.9E–05 9.1E–05 1.9E–05
*These genotype frequency estimates lack precision because of the limited data for
the 1
D allele frequency.
11
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These calculations account for rare mutations undetectable by
the method described here, and model the ‘‘2+0’’ carrier
genotype. Adjusted carrier risk was calculated for each ethnic
group based on its unique allele frequencies (table 4). The result
for the Caucasian population (1:632) is similar to that
previously reported by Smith et al (1:648).
16 In that report
calculations were based on data from a compilation of studies
from countries in Europe, USA, and Australia. The adjusted risk
estimate in the Ashkenazi Jewish population (1:350) is
approximately two times higher than the Caucasian group
because of the higher frequency of two-copy alleles. As
expected, the unusually high frequency of two-copy alleles in
the African American population produces an adjusted risk
factor more than five times greater than that of Caucasians or
Asians. Additionally, a ‘‘3+0’’ genotype carrier has been
previously inferred but not been formally demonstrated by
molecular techniques.
15 The adjusted carrier risk calculations for
the three-copy genotype are presented in the right hand column
of table 4. Finally, using these calculated frequencies, the
negative predictive value and detection rate were determined for
real-time PCR quantification of exon 7 as a screening method
for each ethnic group (table 5).
DISCUSSION
The genetic basis for the unusually high SMN1 copy number in
the African American population is unknown. Previously
published data have shown that individuals with higher copy
numbers of SMN1 tend to have fewer copies of SMN2.
22 It has
been suggested that this correlation indicates that SMN2 may
have converted to SMN1; however, the inverse may also be true.
Alleles with multiple copies of SMN1 may be the ancestral form
of the duplication, with conversion to SMN2 a more recent
mutation event. An assessment of SMN2 copy number is
currently underway to understand the SMN1/SMN2 correla-
tion in this sample set.
Prediction of disease phenotype in SMA is complicated by the
modifying effects of SMN2 copy number, as well as other genes
such as plastin 3.
23 Additionally, there is not a completely
predictive correlation between phenotype and modifiers. Similar
to other autosomal diseases with variable phenotypes, SMA
carrier screening results cannot predict the disease phenotype
for offspring. Although this study has demonstrated that
significant differences exist in SMA carrier frequency between
several ethnic groups, an assessment of pregnancy outcomes
data for these populations will be needed to determine if disease
frequencies or phenotype incidences also vary. More widespread
carrier screening will aid in identifying couples at risk of having
SMA offspring and allow for appropriate follow-up to answer
these questions.
The recent ACMG guideline for SMA carrier screening
17
recommends that since SMA is present in all populations,
carrier testing should be offered to couples regardless of race or
ethnicity who are pregnant or considering pregnancy. The
results from this study provide precise estimates of allele
frequencies and genotypes that vary significantly among ethnic
groups. The implications of this work are most significant for
Hispanic patients who carry lower risks of SMN1 mutations
and for African American patients who bear increased frequen-
cies of two-copy alleles. These data will facilitate the accurate
interpretation of clinical testing results and provide additional
information for genetic counselling.
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